It all comes down to the ATCOR launch and sales pipeline materializing. In the 4C they said they should have news on some contract wins in 4-6 weeks. We are at the 4 week mark now so hopefully something should drop soon.
licensing of its SphygmoCor® technology to third-party medical
device companies. We anticipate an announcement regarding the first of these new efforts in the next
4-6 weeks
the revenue base is low as they are only running one product. With the launch of ATCOR followed by wearable products next year we should see significant increase (from the medical/trial side first).
Of course, that's all based on the fact that they are being fully transparent. Guess that's why this is a spec stock!
Add to My Watchlist
What is My Watchlist?
